Compare CLGN & FEED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLGN | FEED |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | Israel | United States |
| Employees | N/A | 14 |
| Industry | Industrial Specialties | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0M | 5.6M |
| IPO Year | 2015 | N/A |
| Metric | CLGN | FEED |
|---|---|---|
| Price | $0.31 | $0.38 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $11.00 | N/A |
| AVG Volume (30 Days) | 31.9K | ★ 286.2K |
| Earning Date | 05-27-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $240.45 | N/A |
| Revenue Next Year | $38.03 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | $0.35 |
| 52 Week High | $3.23 | $6.09 |
| Indicator | CLGN | FEED |
|---|---|---|
| Relative Strength Index (RSI) | 39.88 | 28.75 |
| Support Level | $0.30 | N/A |
| Resistance Level | $0.44 | $0.97 |
| Average True Range (ATR) | 0.03 | 0.04 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 11.60 | 14.92 |
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
ENvue Medical Inc develops medical devices for enhanced navigation in clinical procedures. The company provides personalized navigation technology to assist clinicians in placing feeding tubes safely and efficiently. Its ENvue system uses smart feeding tubes with sensors, body mapping, and continuous visual guidance to confirm accurate positioning and reduce complications like lung misplacement. The company conducted the business through two primary operating segments: NanoVibronix and ENvue. The firm generates the majority of its revenue from NanoVibronix, which derives revenues from selling its products directly to patients as well as through distributor agreements. ENvue derives revenues from selling its Systems and Nasoenteral tubes.